action of glp-1 agonist Frontiers Video: Non-insulin injectable antidiabetic drugs
Description
Trulicity FDA Approval History , (Jan 28, 2021)
This pathway has been beautifully illustrated by Krajnc et al
However, the half-life of GLP-1 is too short at 1 to 2 minutes, making it difficult to use as a drug [21]
Supported by emerging clinical evidence
Despite the similarly large decreases in body weight, the Sema group showed significant lean mass loss compared to the control group during the 4-week treatment period, while the Sema + -MSTN/-ActA group was not only protected against this lean mass loss, but also had a significant increase in lean mass (Fig
